We searched the Cochrane Library and MEDLINE with the term “gout” for articles published in English between Aug 1, 2010, and Jan 31, 2016. We largely selected publications from the past 5 years, but did not exclude commonly referenced and highly regarded older publications. We also searched the reference lists of articles identified by this search strategy and selected those we judged relevant. Review articles and book chapters are cited to provide readers with more details and more references
SeminarGout
Introduction
Gout is a common and treatable form of inflammatory arthritis that affects almost 4% of adults in the USA.1 The central pathological feature of gout is chronic deposition of monosodium urate crystals, which form in the presence of increased urate concentrations.2 The clinical features of gout occur as a result of the inflammatory response to monosodium urate crystals, and treatment strategies that achieve crystal dissolution are central to effective gout management.3 In the past decade, major progress has been made in understanding of the pathogenesis, impact, diagnostic approaches to, and treatment of this disorder. In this Seminar, we provide a summary of these advances with a focus on clinical management of gout.
Section snippets
Hyperuricaemia
The progression of gout can be defined by four pathophysiological stages: hyperuricaemia without evidence of monosodium urate crystal deposition or gout, crystal deposition without symptomatic gout, crystal deposition with acute gout flares, and advanced gout characterised by tophi, chronic gouty arthritis, and radiographic erosions.4 Progression from one stage to the next is not inevitable.
Pathological hyperuricaemia has been defined as the serum urate concentration (408 μmol/L [6·8 mg/dL])
Incidence and prevalence
In UK and US studies, the incidence of gout varies from 0·30 per 1000 person-years in the 1970s, to 2·68 per 1000 person-years in the 2000s.20 In western developed countries, contemporary prevalence of gout is 3–6% in men and 1–2% in women.20 Prevalence steadily increases with age, but plateaus after 70 years of age.20 Lower prevalences have been reported in developing countries—typically less than 1%.20, 21 Differences in health-care systems or case ascertainment might account for some of
Presentation
Typically, gout presents for the first time as an acute episode of inflammation (flare) affecting the foot or ankle.18 The first flare occurs after an asymptomatic period of hyperuricaemia. It is self-limiting during 1–2 weeks, with complete resolution in signs and symptoms of joint inflammation during the so-called intercritical period. If hyperuricaemia persists, recurrent flares can occur, which become increasingly frequent and prolonged and affect many joints (polyarticular flares),
Principles of management
Gout management includes rapid treatment of acute flares and effective long-term management (table 2).3, 99, 100, 101 The central strategy for long-term management is reduction of serum urate to a concentration that achieves dissolution of monosodium urate crystals. According to the 2012 American College of Rheumatology guidelines, urate-lowering therapy is indicated for those with recurrent gout flares (>1 flare a year), tophi, stage 2 or worse chronic kidney disease, or kidney stones (table 2
Controversies and uncertainties
Although the central cause of gout is well known and effective treatments are available, many uncertainties remain and understanding about pathogenesis is incomplete (panel 2). For example, why some individuals with hyperuricaemia develop monosodium urate crystal deposition and others do not is unknown. Why monosodium urate crystals preferentially deposit at specific sites and why deposited crystals can be present in the joint without clinically apparent inflammation is also unclear. The causal
Conclusion
Despite major progress in the understanding of pathogenesis and therapeutic advances, the prevalence of gout is increasing and many patients have poorly controlled disease. Gout is a treatable disease and the strategy of long-term lowering of serum urate concentrations is highly effective in removing monosodium urate crystals. Implementation of this strategy necessitates focused attention to prevent the serious consequences of this disease.
Search strategy and selection criteria
References (153)
- et al.
Causal assessment of serum urate levels in cardiometabolic diseases through a mendelian randomization study
J Am Coll Cardiol
(2016) - et al.
Mendelian randomization analysis associates increased serum urate, due to genetic variation in uric acid transporters, with improved renal function
Kidney Int
(2014) - et al.
A genetic marker of uric acid level, carotid atherosclerosis, and arterial stiffness: a family-based study
Am J Kidney Dis
(2015) - et al.
Gout and the risk of dementia: a nationwide population-based cohort study
Arthritis Res Ther
(2015) - et al.
Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study
Am J Med
(1987) - et al.
Alcohol consumption as a trigger of recurrent gout attacks
Am J Med
(2006) - et al.
The broad spectrum of urate crystal deposition: unusual presentations of gouty tophi
Semin Arthritis Rheum
(2012) - et al.
Synovial fluid analysis
Best Pract Res Clin Rheumatol
(2005) - et al.
“Crystal clear”-sonographic assessment of gout and calcium pyrophosphate deposition disease
Semin Arthritis Rheum
(2006) - et al.
Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008
Arthritis Rheum
(2011)
Identification of urate crystals in gouty synovial fluid
Ann Intern Med
2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia
Arthritis Care Res
Hyperuricaemia and gout: time for a new staging system?
Ann Rheum Dis
The influence of temperature on the solubility of monosodium urate
Arthritis Rheum
Decreased extra-renal urate excretion is a common cause of hyperuricemia
Nat Commun
Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output
Arthritis Rheum
The molecular physiology of uric acid homeostasis
Annu Rev Physiol
Cellular characterization of the gouty tophus: a quantitative analysis
Arthritis Rheum
Monocytes and granulocytes orchestrate induction and resolution of inflammation in gout
Gout Hyperuric
Factors influencing the crystallization of monosodium urate: a systematic literature review
BMC Musculoskelet Disord
Monosodium urate monohydrate crystallization
CrystEngComm
Gout-associated uric acid crystals activate the NALP3 inflammasome
Nature
Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome
Nat Immunol
Engagement of fatty acids with toll-like receptor 2 drives interleukin-1β production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis
Arthritis Rheum
Mechanistic aspects of inflammation and clinical management of inflammation in acute gouty arthritis
J Clin Rheumatol
Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines
Nat Med
Diagnosis and treatment of gout and gouty arthritis
JAMA
Mechanisms of bone erosion in gout: a quantitative analysis using plain radiography and computed tomography
Ann Rheum Dis
Global epidemiology of gout: prevalence, incidence and risk factors
Nat Rev Rheumatol
The global burden of gout: estimates from the Global Burden of Disease 2010 study
Ann Rheum Dis
National prevalence of gout derived from administrative health data in Aotearoa New Zealand
Rheumatology
Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study
Ann Rheum Dis
Gout epidemiology: results from the UK general practice research database, 1990–1999
Ann Rheum Dis
Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007–2008
Am J Med
Independent impact of gout on mortality and risk for coronary heart disease
Circulation
Serum uric acid and adiposity: deciphering causality using a bidirectional mendelian randomization approach
PLoS One
Association of plasma uric acid with ischaemic heart disease and blood pressure: mendelian randomisation analysis of two large cohorts
BMJ
Plasma urate concentration and risk of coronary heart disease: a mendelian randomisation analysis
Lancet Diabetes Endocrinol
A mendelian randomization study of circulating uric acid and type 2 diabetes
Diabetes
Uric acid and cardiovascular events: a mendelian randomization study
J Am Soc Nephrol
Association of a polymorphism in a gene encoding a urate transporter with CKD progression
Clin J Am Soc Nephrol
Clinical associations between gout and multiple sclerosis, Parkinson's disease and motor neuron disease: record-linkage studies
BMC Neurol
Gout and the risk of Alzheimer's disease: a population-based, BMI-matched cohort study
Ann Rheum Dis
Plasma urate and risk of Parkinson's disease
Am J Epidemiol
Uric acid provides an antioxidant defense in humans against oxidant-and radical-caused aging and cancer: a hypothesis
Proc Natl Acad Sci USA
Epidemiology of gout in women: Fifty-two-year followup of a prospective cohort
Arthritis Rheum
Risk factors for gout and prevention: a systematic review of the literature
Curr Opin Rheumatol
Purine-rich foods intake and recurrent gout attacks
Ann Rheum Dis
Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study
BMJ
Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: the third National Health and Nutrition Examination Survey
Arthritis Rheum
Cited by (797)
Association between serum uric acid and deep venous thrombosis in European populations: A two-sample Mendelian randomization study
2024, Nutrition, Metabolism and Cardiovascular DiseasesMechanistic insights into the C-type lectin receptor CLEC12A-mediated immune recognition of monosodium urate crystal
2024, Journal of Biological ChemistryNod-like receptors in inflammatory arthritis
2024, Biomedical Journal